ABSTRACT
BACKGROUND: Since the beginning of the pandemic, new knowledge about COVID-19 obtained by research has been disseminated in medical and scientific journals, but the large number of publications that have been generated in such a short time has been impressive. OBJECTIVE: To perform a bibliometric analysis of the published articles in medical-scientific journals carried-out by the Mexican Social Security Institute (IMSS) personnel on COVID-19. MATERIAL AND METHODS: Systematic review of the literature, identifying the publications included in the PubMed and EMBASE databases, up to September 2022. Articles on COVID-19 were included, in which at least one author had IMSS affiliation;there was no restriction on the type of publication, so original articles, review articles, clinical case reports, etc. were included. The analysis was descriptive. RESULTS: 588 abstracts were obtained, of which 533 full length articles met the selection criteria. Most were research articles (48%), followed by review articles. Mainly clinical or epidemiological aspects were addressed. They were published in 232 different journals, with a predominance of foreign journals (91.8%). Around half of the publications were carried out by IMSS personnel together with authors from other institutions, national or foreign. CONCLUSIONS: The scientific contributions prepared by IMSS personnel have contributed to understanding clinical, epidemiological and basic aspects of COVID-19, which has had an impact on improving the quality of care for its beneficiaries.
ABSTRACT
On December 2019, a new virus was announced as the cause of an outbreak of severe pneumonia in China. WHO declared the SARS-CoV-2 pandemic due to the rising cases worldwide On March 11th 2020. The incubation period ranges from 1-12.5 days (average 5-6 days) and its transmission is by droplets, and direct contact, with an unclear transmission during aerosol-generating procedures in the community setting. In almost all pediatric cases, a household contact is the source of infection, and most of these patients are asymptomatic and have a mild respiratory condition. However, few patients develop severe manifestations such as pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) which consists in a wide spectrum of clinical manifestations with hyperinflammatory symptoms that include prolonged fever, hypovolemia and shock that may lead to death. Unfortunately, there is no specific treatment approved for use in pediatric patients, despite the time that has passed and multiple different research studies have been conducted. For this reason, management must continue to be based on supportive treatment and timely case identification. This document aims to guide the management of pediatric patients suspected or confirmed of COVID-19, according to the findings of research studies conducted through January 2021.